

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

For the Examiner's convenience, all the pending claims are reproduced below, whether or not amended. Please amend claims 26 and 27 as follows:

- 1-17. (Canceled).
18. (Previously presented) A method of obtaining an antibody, comprising:
providing a mammal that (a) has a pro-B cell which is Aiolos (SEQ ID NO:2 or 30)
deregulated and (b) is immunized with an antigen recognized by the pro-B cell; and
isolating an antibody against the antigen from the mammal or from a B cell derived from
the mammal, to thereby obtain an antibody.
19. (Original) The method of claim 18, wherein the mammal is a mouse.
20. (Original) The method of claim 18, wherein the mammal is an Aiolos transgenic
mouse.
21. (Previously presented) The method of claim 18, wherein the antigen is an
autoantigen.
22. (Previously presented) The method of claim 18, wherein the mammal is
immunized with an alloantigen or xenoantigen.
23. (Original) The method of claim 22, wherein the antigen is poorly antigenic in wild
type animals.

24. (Previously presented) The method of claim 22, wherein the antigen has at least 90% homology between the first and second species as determined using the ALIGN program with a PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4 or using XBLAST with default parameters, wherein the first species is the animal which provides the antibody and the second species is the species which provides the antigen.

25. (Original) The method of claim 18, wherein the antibody is an IgG antibody.

26. (Currently amended) The method of claim 18, wherein the mammal carries homozygous null mutations at the Aiolos gene.

27. (Currently amended) The method of claim 18, ~~the method further comprises~~ comprising isolating one or more B cells from the mammal and isolating the antibody ~~therefrom~~ from the isolated B-cells.

28. (Previously presented) The method of claim 18, wherein the B cell from the animal is fused with a second cell to provide a hybridoma and the antibody is isolated from the hybridoma.

29. (Previously presented) A method of obtaining an antibody comprising:
providing a mouse that (a) has a pro-B cell which is homozygous for null or underexpressing mutations at the Aiolos (SEQ ID NO:2) locus and (b) is immunized with an antigen recognized by the pro-B cell; and
isolating an antibody against the antigen from the mouse, to thereby obtain an antibody.

30. (Original) The method of claim 29, wherein the mouse is an Aiolos transgenic mouse.

31. (Previously presented) The method of claim 29, wherein the antigen is an autoantigen.

32. (Previously presented) The method of claim 29, wherein the mouse is immunized with an alloantigen or xenoantigen.

33. (Original) The method of claim 32, wherein the antigen is poorly antigenic in wild type animals.

34. (Previously presented) The method of claim 32, wherein the antigen has at least 90% homology between the first and second species as determined using the ALIGN program with a PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4 or using XBLAST with default parameters, wherein the first species is the animal which provides the antibody and the second species is the species which provides the antigen.

35. (Previously presented) A method of obtaining a monoclonal antibody, comprising:

providing a mouse that (a) has a pro-B cell which is homozygous for null or underexpressing mutations at the Aiolos (SEQ ID NO:2) locus and (b) is immunized with an antigen recognized by the pro-B cell;

isolating a B cell from the mouse; and

isolating an antibody against the antigen from the B cell or a derivative of the cell, to thereby obtain an antibody.

37. (Canceled)

36. (Original) The method of claim 35, wherein the derivative is a hybridoma.

38. (Original) The method of claim 35, wherein the mouse is an Aiolos transgenic mouse.

39. (Previously presented) The method of claim 35, wherein the antigen is an autoantigen.

40. (Previously presented) The method of claim 35, wherein the mouse is immunized with an alloantigen or xenoantigen.

41. (Original) The method of claim 35, wherein the antigen is poorly antigenic in wild type animals.

42. (Previously presented) The method of claim 18, wherein the mammal is homozygous for a deletion of exon 7 of the Aiolos gene or a portion thereof.

43. (Previously presented) The method of claim 29, wherein the mouse is homozygous for a deletion of exon 7 of the Aiolos gene or a portion thereof.

44. (Previously presented) The method of claim 35, wherein the mouse is homozygous for a deletion of exon 7 of the Aiolos gene or a portion thereof.